AKUMS Share Price Performance
₹0
-470.65 (-100.00%)
Price ₹0
Fair Value₹780.00
Share Pricen/a
Analysis Article • Aug 12
Akums Drugs and Pharmaceuticals Limited Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
AKUMS Community Narratives
AN
Fair Value
·Fair Value ₹780 6.8% undervalued intrinsic discount
Global Expansion In Europe, Brazil And India Will Unlock Opportunities
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
Fair Value
·Fair Value ₹610 19.1% overvalued intrinsic discount
Capital-Heavy Capacity Expansion And API Losses Will Pressure Margins Over Time
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Capital-Heavy Capacity Expansion And API Losses Will Pressure Margins Over Time
Akums is spending heavily to expand factories and build out its own brands, while one of its divisions is still losing money. If costs stop falling in its favor or new capacity doesn’t fill up fast enough, profits could come under pressure even if sales keep growing.Read more
AN
₹610
19.1% overvalued intrinsic discount
Fair Value
Revenue
15.54% p.a.
Profit Margin
10.74%
Future PE
18.39x
Price in 2029
₹893.23
Global Expansion In Europe, Brazil And India Will Unlock Opportunities
Akums is pushing beyond India into tightly regulated markets like Europe and Brazil, betting that new approvals and launches can open fresh demand and improve what it earns from each product. But its plan has to overcome weak pricing, slow growth in some core lines, and the challenge of building overseas sales channels without missteps.Read more
AN
₹780
6.8% undervalued intrinsic discount
Fair Value
Revenue
14.39% p.a.
Profit Margin
10.97%
Future PE
23.61x
Price in 2029
₹1.14k
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
AKUMS: Upcoming Board Schedule And Special Dividend Will Shape Earnings Outlook
Fair Value: ₹780 6.8% undervalued intrinsic discount
7 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Capital-Heavy Capacity Expansion And API Losses Will Pressure Margins Over Time
Fair Value: ₹610 19.1% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Akums Drugs and Pharmaceuticals Limited Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 04, 2026
- 19.05
- 41.09%
- 6.48%
- 5.8%
About AKUMS
- Founded
- 2004
- Employees
- 7337
- CEO
- WebsiteView website
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies for therapeutic areas, such as antiinfectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology. In addition, the company operates as pharmaceutical contract development and manufacturing company. Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and is based in Delhi, India.
Recent AKUMS News & Updates
Narrative Update • Aug 11
AKUMS: Upcoming Board Schedule And Special Dividend Will Shape Earnings Outlook
Analysts have lifted their price target on Akums Drugs and Pharmaceuticals from ₹730 to ₹780, citing updated estimates that reflect the new fair value, an adjusted discount rate, revised revenue growth assumptions, higher profit margin forecasts and a lower future P/E multiple. What's in the News Akums Drugs and Pharmaceuticals has scheduled a board meeting on Aug 08, 2026, at 13:30 Indian Standard Time to consider and approve the unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2026.
New Narrative • Aug 11
